NYSE:RBOT Vicarious Surgical Q4 2025 Earnings Results & Report $0.05 0.00 (0.00%) As of 10/14/2026 03:32 PM Eastern Vicarious Surgical missed analyst earnings expectations in its Q4 2025 results, released March 9, 2026. The company reported EPS of -$1.65 versus the -$1.37 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 9, 2026TimeBefore Market OpensConference Call7:00 AM ET Vicarious Surgical EPS ResultsActual EPS-$1.65Consensus EPS -$1.37Beat/MissMissed by -$0.28One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersVicarious Surgical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsVicarious Surgical's Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Vicarious Surgical Q4 2025 Earnings FAQ Did Vicarious Surgical beat earnings estimates for Q4 2025? Vicarious Surgical (NYSE:RBOT) reported earnings of -$1.65 per share for Q4 2025, missing the consensus estimate of -$1.37. The report was announced on Monday, March 9, 2026. When is Vicarious Surgical's next earnings date? Vicarious Surgical's next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Vicarious Surgical on the company's earnings history page. Vicarious Surgical Earnings HeadlinesSS Innovations names Sarah Romano as CFOJuly 15, 2026 | finance.yahoo.comVicarious Surgical board proposes dissolving the companyJuly 15, 2026 | finance.yahoo.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 15 at 1:00 AM | Stansberry Research (Ad)Vicarious Surgical Demonstrates Sustained System Performance and Complex Hernia Procedure Workflows in Pre-Clinical SettingMay 13, 2026 | globenewswire.comVicarious Surgical Reports First Quarter 2026 Financial ResultsApril 30, 2026 | globenewswire.comVicarious Surgical Shareholders Approve Reverse Stock Split AuthorizationApril 8, 2026 | tipranks.comSee More Vicarious Surgical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vicarious Surgical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vicarious Surgical and other key companies, straight to your email. Email Address About Vicarious SurgicalVicarious Surgical (NYSE:RBOT), Inc. is a technology company developing robotic-assisted surgical systems. Its principal product is the Vicarious Surgical System, a single-port robotic platform designed to enable surgeons to perform minimally invasive procedures through a small incision. The system combines miniature instruments, a high-resolution camera and digital controls intended to provide surgeons with an immersive view of the operating field and precise instrument control. The company’s technology is aimed initially at general surgery applications, including procedures performed within the abdominal cavity. Vicarious Surgical has focused on developing a compact robotic system that can provide multi-axis instrument movement and visualization while potentially reducing the size and complexity of surgical access. Its products remain subject to regulatory review and authorization, and the company’s activities have primarily involved research, development and clinical evaluation rather than broad commercial deployment. Vicarious Surgical was founded in 2014 and became a publicly traded company in 2021 through a business combination with D8 Holdings Corp. The company is based in Waltham, Massachusetts, and has concentrated its regulatory and development efforts in the United States. Co-founder Adam Sachs has served as the company’s chief executive officer and has been involved in guiding the development of its robotic surgery platform.View Vicarious Surgical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenUnitedHealth Beats on Earnings, But Investors Question Growth PathIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
